Published in Stat Med on February 01, 2009
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Assessing improvement in disease prediction using net reclassification improvement: impact of risk cut-offs and number of risk categories. Eur J Epidemiol (2012) 1.75
Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. Med Decis Making (2013) 1.13
Improvements in ability to detect undiagnosed diabetes by using information on family history among adults in the United States. Am J Epidemiol (2010) 1.05
Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China. Oncotarget (2017) 0.75
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making (2006) 11.83
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ (2008) 4.60
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Empirical study of data sharing by authors publishing in PLoS journals. PLoS One (2009) 4.09
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. BMJ (2010) 3.38
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol (2009) 3.04
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak (2008) 2.64
Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer (2009) 2.63
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials (2010) 2.54
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol (2009) 2.11
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ (2004) 2.03
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int (2006) 2.00
Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol (2010) 1.93
Decision curve analysis: a discussion. Med Decis Making (2008) 1.87
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med (2010) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer (2006) 1.75
Causes of death in long-term survivors of head and neck cancer. Cancer (2014) 1.68
Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. J Urol (2010) 1.66
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer (2011) 1.62
Acupuncture in the treatment of upper-limb lymphedema: results of a pilot study. Cancer (2013) 1.62
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer (2008) 1.62
Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage (2004) 1.60
Critical review of prostate cancer predictive tools. Future Oncol (2009) 1.57
Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer (2006) 1.53
A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int (2013) 1.51
Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol (2012) 1.50
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy. Eur Urol (2011) 1.50
Comparison of three different tools for prediction of seminal vesicle invasion at radical prostatectomy. Eur Urol (2012) 1.50
Is it necessary to remove the seminal vesicles completely at radical prostatectomy? decision curve analysis of European Society of Urologic Oncology criteria. J Urol (2008) 1.50
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest (2011) 1.46
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J Clin Oncol (2012) 1.44
External validation of a prognostic model predicting time of death after withdrawal of life support in neurocritical patients. Crit Care Med (2012) 1.43
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J (2006) 1.42
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res (2008) 1.42
Tools & Techniques: Analysis of clustered data in interventional cardiology: current practice and methodological advice. EuroIntervention (2013) 1.41
Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol (2007) 1.41
Reducing systematic review to a cut and paste. Forsch Komplementmed (2010) 1.40
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Geographic proximity to treatment for early stage breast cancer and likelihood of mastectomy. Breast (2011) 1.35
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol (2006) 1.32
Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol (2010) 1.30
Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer (2009) 1.29
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol (2010) 1.27
Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer (2011) 1.26
Making raw data more widely available. BMJ (2011) 1.25
Do the data support the comorbidity hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial results? J Clin Oncol (2011) 1.24
Fellowship training as a modifier of the surgical learning curve. Acad Med (2010) 1.24
Benchmarking lung cancer mortality rates in current and former smokers. Chest (2004) 1.23
Acupuncture for tension-type headache: a multicentre, sham-controlled, patient-and observer-blinded, randomised trial. J Headache Pain (2007) 1.22
Hospital standardized mortality ratio: consequences of adjusting hospital mortality with indirect standardization. PLoS One (2013) 1.20
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol (2006) 1.20
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol (2005) 1.18
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Ethnic differences in bladder cancer survival. Urology (2011) 1.17
Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer (2011) 1.16
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer (2005) 1.15
Statistical methods to correct for verification bias in diagnostic studies are inadequate when there are few false negatives: a simulation study. BMC Med Res Methodol (2008) 1.14
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol (2007) 1.13
Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. Med Decis Making (2013) 1.13
Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med (2014) 1.12
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. Eur Urol (2013) 1.12
Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol (2011) 1.10
Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. Cancer (2003) 1.09
Lessons learned from 416 cases of nipple discharge of the breast. Am J Surg (2010) 1.09
Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology (2007) 1.08
The surgical learning curve for artificial urinary sphincter procedures compared to typical surgeon experience. Eur Urol (2011) 1.06